Ecallantide
Showing 1 - 11 of 11
Hereditary Angioedema (HAE) Trial (ecallantide)
Withdrawn
- Hereditary Angioedema (HAE)
- ecallantide
- (no location specified)
May 14, 2021
Hereditary Angioedema (HAE) Trial in Wheaton (ecallantide, Phosphate Buffer Saline (PBS),)
Completed
- Hereditary Angioedema (HAE)
- ecallantide
- Phosphate Buffer Saline (PBS),
-
Wheaton, MarylandInstitute for Asthma and Allergy
Jun 3, 2021
Hereditary Angioedema (HAE) Trial (DX-88 (ecallantide))
Completed
- Hereditary Angioedema (HAE)
- DX-88 (ecallantide)
- (no location specified)
May 14, 2021
Hereditary Angioedema (HAE) Trial in Canada, Jordan, United States (ecallantide)
Completed
- Hereditary Angioedema (HAE)
- ecallantide
-
Scottsdale, Arizona
- +40 more
May 14, 2021
Hereditary Angioedema (HAE) Trial in Canada, Jordan, United States (ecallantide, Phosphate Buffer Saline (PBS), pH 7.0)
Completed
- Hereditary Angioedema (HAE)
- ecallantide
- Phosphate Buffer Saline (PBS), pH 7.0
-
Scottsdale, Arizona
- +44 more
May 14, 2021
Blood Loss, Surgical Trial in United States (Ecallantide, Placebo)
Terminated
- Blood Loss, Surgical
- Ecallantide
- Placebo
-
Birmingham, Alabama
- +14 more
Jun 17, 2019
Hereditary Angioedema Types I and II Trial in Mineola (Ecallantide subcutaneous dosing)
Unknown status
- Hereditary Angioedema Types I and II
- Ecallantide subcutaneous dosing
-
Mineola, New YorkWinthrop-University Hosptial Clinical Trials Center
Jan 3, 2017
Bloodloss, Surgical Procedures, Operative Trial in Canada, United States (ecallantide, )
Completed
- Bloodloss
- Surgical Procedures, Operative
- ecallantide
- placebo
-
Birmingham, Alabama
- +28 more
Jul 21, 2015
Bloodloss, Surgical Procedures, Operative Trial in Germany, Poland, United States (Ecallantide, Cyklokapron(R))
Completed
- Bloodloss
- Surgical Procedures, Operative
- Ecallantide
- Cyklokapron(R)
-
Birmingham, Alabama
- +33 more
Jul 21, 2015
Angioedema Trial in Cincinnati (ecallantide - Kallikrein inhibitor that blocks the production of bradykinin)
Unknown status
- Angioedema
- ecallantide - Kallikrein inhibitor that blocks the production of bradykinin
-
Cincinnati, Ohio
- +2 more
Mar 8, 2012
Macular Edema, Central Retinal Vein Occlusion Trial in France (FOV2302 (Ecallantide))
Terminated
- Macular Edema
- Central Retinal Vein Occlusion
- FOV2302 (Ecallantide)
-
Amiens, France
- +7 more
Jan 9, 2012